LVTX 外匯新聞
LAVA Therapeutics Appoints Dr. Charles Morris As Chief Medical Officer
Immuno-oncology company LAVA Therapeutics N.V. (LVTX) announced Monday that Dr. Charles Morris has joined LAVA as chief medical officer effective February 6, 2023. Dr. Morris will replace Benjamin Winograd.
RTTNews
|
622天前
Seagen, LAVA Therapeutics Ink Worldwide License Agreement To Develop And Commercialize LAVA-1223
Seagen Inc. (SGEN), a pioneer in antibody-drug conjugate (ADC) therapies, and LAVA Therapeutics N.V. (LVTX), a clinical-stage immuno-oncology company, announced Monday an exclusive license agreement in which Seagen will work to develop, manufacture and commercialize LAVA-1223.
RTTNews
|
755天前
